Does INOTUZUMAB OZOGAMICIN Cause Second primary malignancy? 18 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Second primary malignancy have been filed in association with INOTUZUMAB OZOGAMICIN (Besponsa). This represents 0.8% of all adverse event reports for INOTUZUMAB OZOGAMICIN.
18
Reports of Second primary malignancy with INOTUZUMAB OZOGAMICIN
0.8%
of all INOTUZUMAB OZOGAMICIN reports
9
Deaths
7
Hospitalizations
How Dangerous Is Second primary malignancy From INOTUZUMAB OZOGAMICIN?
Of the 18 reports, 9 (50.0%) resulted in death, 7 (38.9%) required hospitalization, and 7 (38.9%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for INOTUZUMAB OZOGAMICIN. However, 18 reports have been filed with the FAERS database.
What Other Side Effects Does INOTUZUMAB OZOGAMICIN Cause?
Death (253)
Febrile neutropenia (230)
Venoocclusive liver disease (229)
Neoplasm progression (158)
Pyrexia (151)
Off label use (146)
Sepsis (119)
Venoocclusive disease (109)
Thrombocytopenia (108)
Platelet count decreased (107)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which INOTUZUMAB OZOGAMICIN Alternatives Have Lower Second primary malignancy Risk?
INOTUZUMAB OZOGAMICIN vs INSULIN
INOTUZUMAB OZOGAMICIN vs INSULIN ASPART
INOTUZUMAB OZOGAMICIN vs INSULIN ASPART\INSULIN DEGLUDEC
INOTUZUMAB OZOGAMICIN vs INSULIN BEEF
INOTUZUMAB OZOGAMICIN vs INSULIN DEGLUDEC